Vertex Pharmaceuticals Incorporated
VRTX
$424.99
-$4.61-1.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.22% | -5.76% | 0.98% | -492.44% | 57.13% |
| Total Depreciation and Amortization | -9.53% | -54.87% | 26.37% | 30.43% | 37.89% |
| Total Amortization of Deferred Charges | -- | 113.56% | -- | -- | -- |
| Total Other Non-Cash Items | 1,522.73% | 305.47% | 5,314.29% | 140.23% | 8.04% |
| Change in Net Operating Assets | -307.66% | 33.22% | -16.62% | -198.37% | -6.91% |
| Cash from Operations | -37.33% | 149.19% | 7.99% | -430.89% | 45.19% |
| Capital Expenditure | 40.50% | -59.38% | -66.75% | -15.77% | -62.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.27% | 11.96% | -263.55% | -61.56% | -15.43% |
| Cash from Investing | 97.39% | 7.29% | -195.67% | -52.58% | -16.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 90.15% | 89.17% | 52.21% | -24.55% | -24.53% |
| Issuance of Common Stock | -1.18% | -26.08% | -45.45% | -6.14% | 19.01% |
| Repurchase of Common Stock | -91.01% | -178.45% | -129.96% | -1,176.43% | -21.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.14% | 160.00% | -18.18% | -18.18% | 218.18% |
| Cash from Financing | -90.32% | -226.63% | -134.85% | -2,172.83% | -21.31% |
| Foreign Exchange rate Adjustments | 295.51% | -272.63% | 201.33% | -125.00% | -230.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.41% | 9.19% | -31.78% | -633.74% | 1.11% |